Cancer is a worldwide health problem and despite advances in traditional treatments i.e. surgery, chemotherapy and radiotherapy, the cure rate remains disappointing for some cancers. Different novel therapeutic strategies are being developed. In this thesis two nontraditional cancer therapy approaches are studied: gene therapy using viral vectors and antitumour vaccination with dendritic cell - tumour cell (DC/TC) hybrids.
We have developed a novel ELISPOT titration method for viral vectors that is based on the actual expression of the transgene in target cells. This method was developed with recombinant parvovirus MVM-IL2, but it should be adaptable for other vectors carrying expression cassettes for secreted transgene products for which antibodies are available. The ELISPOT titration method allows for faster and better quantification of transducing units present in vector stocks as opposed to titration by in situ hybridisation (annexe I). The MVMIL2 vector has shown an anti-tumour effect against melanoma in an immunocompetent mouse model (annexe IV). Previous work concerns photodynamic inactivation of adenoviral vectors for biosafety and an in vivo study in which a synergistic effect of antiangiogenesis gene therapy combined with radiotherapy could be shown (annexes V and VI).
DC/TC hybrids have been proposed as cancer vaccines for their simultaneous expression of antigen presentation machinery and tumour associated antigens. Hybrids are classically generated by polyethylene glycol (PEG) or electrofusion. These methods however require special skills and equipment and cause rather high cell lethality. Fusion via the expression of viral fusogenic membrane glycoproteins (FMG), such as the vesicular stomatitis virus-G (VSV-G) (annexe III) or the Gibbon ape Leukemia Virus (GaLV) FMG, have recently been described. We have mainly focussed on the latter. Transduction of cells with GaLV-FMG proved to be a limiting step for an efficient generation of hybrids. On the other hand, constitutive expression of GaLV-FMG leads to lethal syncytia formation in human cells. Therefore we developed a novel fusion strategy for the generation of DC/TC cell hybrids that involves the use of a non-human fusogenic cell line that constitutively expresses the GaLV-FMG. With this method we were able to generate reproducible yields of DC/TC triparental hybrids. The formation of tri-parental hybrids via the fusogenic cell line is an interesting alternative to existing DC/TC fusion methods because of its simplicity and its flexibility in the choice of fusion partners, i.e. autologous or allogeneic DCs and tumour cells.
Moreover, the tri-parent hybrid system offers the possibility to further enhance the immune response by the addition of transgenes that code for immuno-modulating factors to the fusogenic cell line (annexe II).
| Identifer | oai:union.ndltd.org:BICfB/oai:ulb.ac.be:ETDULB:ULBetd-04112005-154054 |
| Date | 16 February 2005 |
| Creators | Cheong, Siew Chiat |
| Contributors | Thielemans, Kris, Coulie, Pierre, Martiat, Philippe, Goldman, Michel, De Launoit, Yvan, Velu, Thierry, Brandenburger, Annick, Lebrun, Philippe |
| Publisher | Universite Libre de Bruxelles |
| Source Sets | Bibliothèque interuniversitaire de la Communauté française de Belgique |
| Language | English |
| Detected Language | English |
| Type | text |
| Format | application/pdf |
| Source | http://theses.ulb.ac.be/ETD-db/collection/available/ULBetd-04112005-154054/ |
| Rights | mixed, J'accepte que le texte de la thèse (ci-après l'oeuvre), sous réserve des parties couvertes par la confidentialité, soit publié dans le recueil électronique des thèses ULB. A cette fin, je donne licence à ULB : - le droit de fixer et de reproduire l'oeuvre sur support électronique : logiciel ETD/db - le droit de communiquer l'oeuvre au public Cette licence, gratuite et non exclusive, est valable pour toute la durée de la propriété littéraire et artistique, y compris ses éventuelles prolongations, et pour le monde entier. Je conserve tous les autres droits pour la reproduction et la communication de la thèse, ainsi que le droit de l'utiliser dans de futurs travaux. Je certifie avoir obtenu, conformément à la législation sur le droit d'auteur et aux exigences du droit à l'image, toutes les autorisations nécessaires à la reproduction dans ma thèse d'images, de textes, et/ou de toute oeuvre protégés par le droit d'auteur, et avoir obtenu les autorisations nécessaires à leur communication à des tiers. Au cas où un tiers est titulaire d'un droit de propriété intellectuelle sur tout ou partie de ma thèse, je certifie avoir obtenu son autorisation écrite pour l'exercice des droits mentionnés ci-dessus. |
Page generated in 0.0022 seconds